Literature DB >> 15761719

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

M A Nauck1, A El-Ouaghlidi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15761719     DOI： 10.1007/s00125-005-1704-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  22 in total

1.  Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

Authors:  C F Deacon; T E Hughes; J J Holst
Journal:  Diabetes       Date:  1998-05       Impact factor: 9.461

2.  Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide.

Authors:  R P Pauly; H U Demuth; F Rosche; J Schmidt; H A White; F Lynn; C H McIntosh; R A Pederson
Journal:  Metabolism       Date:  1999-03       Impact factor: 8.694

3.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Authors:  M A Nauck; U Niedereichholz; R Ettler; J J Holst; C Orskov; R Ritzel; W H Schmiegel
Journal:  Am J Physiol       Date:  1997-11

4.  Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.

Authors:  M Kvist Reimer; J J Holst; B Ahrén
Journal:  Eur J Endocrinol       Date:  2002-05       Impact factor: 6.664

Review 5.  The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily.

Authors:  N M Sherwood; S L Krueckl; J E McRory
Journal:  Endocr Rev       Date:  2000-12       Impact factor: 19.871

Review 6.  Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.

Authors:  Michael A Nauck; Birgit Baller; Juris J Meier
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

7.  Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.

Authors:  Béatrice Sudre; Pierre Broqua; Richard B White; Doreen Ashworth; D Michael Evans; Robert Haigh; Jean-Louis Junien; Michel L Aubert
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

8.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Authors:  Juris J Meier; Baptist Gallwitz; Stefan Salmen; Oliver Goetze; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Authors:  Lise L Kjems; Jens J Holst; Aage Vølund; Sten Madsbad
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

10.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Authors:  M A Nauck; M M Heimesaat; C Orskov; J J Holst; R Ebert; W Creutzfeldt
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808
View more
  20 in total

1.  Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

Authors:  J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

2.  What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?

Authors:  B Ahrén
Journal:  Diabetologia       Date:  2005-03-16       Impact factor: 10.122

3.  Mechanism of action of DPP-4 inhibitors--new insights.

Authors:  Adrian Vella
Journal:  J Clin Endocrinol Metab       Date:  2012-08       Impact factor: 5.958

Review 4.  How do different GLP-1 mimetics differ in their actions?

Authors:  Simeon Pierre Choukem; Jean-François Gautier
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

5.  Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

Authors:  Louise Profit; Paul Chrisp; Carole Nadin
Journal:  Core Evid       Date:  2008-06

6.  New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

Authors:  Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2005-08-10

Review 7.  Incretin-based therapies in type 2 diabetes mellitus.

Authors:  Chee W Chia; Josephine M Egan
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

8.  Rapid hepatic metabolism blunts the endocrine action of portally infused GLP-1 in male rats.

Authors:  Benedikt A Aulinger; Marta Perabo; Randy J Seeley; Klaus G Parhofer; David A D'Alessio
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-11-19       Impact factor: 4.310

9.  The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Authors:  Adrian Vella; Gerlies Bock; Paula D Giesler; Duane B Burton; Denise B Serra; Monica Ligueros Saylan; Carolyn F Deacon; James E Foley; Robert A Rizza; Michael Camilleri
Journal:  Clin Endocrinol (Oxf)       Date:  2008-03-10       Impact factor: 3.478

10.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Authors:  P V Højberg; T Vilsbøll; R Rabøl; F K Knop; M Bache; T Krarup; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2008-11-27       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.